DOI QR코드

DOI QR Code

Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients

  • Shankar, Abhishek ;
  • Roy, Shubham ;
  • Malik, Abhidha ;
  • Julka, PK ;
  • Rath, GK
  • Published : 2015.10.06

Abstract

The supportive care of patients receiving antineoplastic treatment has dramatically improved over the past few years and development of effective measures to prevent nausea and vomiting after chemotherapy serves as one of the most important examples of this progress. A patient who starts cancer treatment with chemotherapy lists chemotherapy-induced nausea and vomiting as among their greatest fears. Inadequately controlled emesis impairs functional activity and quality of life, increases the use of health care resources, and may occasionally compromise adherence to treatment. New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a better understanding of the risk factors for these effects, and the availability of new antiemetic agents have all contributed to substantial improvements in emetic control. This review focuses on current understanding of chemotherapy-induced nausea and vomiting and the status of pharmacological interventions for their prevention and treatment.

Keywords

Prevention;chemotherapy;nausea and vomiting;cancer patients

References

  1. Aapro MS, Molassiotis A, Oliver I (2005). Anticipatory nausea and vomiting. Support Care Cancer, 13, 117-21. https://doi.org/10.1007/s00520-004-0745-8
  2. Aapro M, Rugo H, Rossi G et al (2014). A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol, 25, 1328-33. https://doi.org/10.1093/annonc/mdu101
  3. Bergstrom M, Hargreaves RJ, Burns HD, et al (2011). Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci, 1222, 40-8. https://doi.org/10.1111/j.1749-6632.2011.05961.x
  4. Einhorn LH, Brames MJ, Dreicer R, et al (2007). Palonosetron plus dexamethasone for prevention of chemotherapyinduced nausea and vomiting in patients receiving multipleday cisplatin chemotherapy for germ cell cancer. Support Care Cancer, 15, 1293-300. https://doi.org/10.1007/s00520-007-0255-6
  5. Gralla RJ (1993). Current issues in the management of nausea and vomiting. Ann Oncol, 4, 3-7.
  6. Gralla RJ, Bosnjak SM, Hontsa A, et al (2014). A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol, 25, 1333-9. https://doi.org/10.1093/annonc/mdu096
  7. Gralla RJ, Osoba D, Kris MG, et al (1999). Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American society of clinical oncology. J Clin Oncol, 17, 2971.
  8. Grunberg SM, Osoba D, Hesketh PJ, et al (2005). Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer, 13, 80-4. https://doi.org/10.1007/s00520-004-0718-y
  9. Jordan K, Sippel C, Schmoll HJ (2007). Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting: past, present, and future recommendations. Oncologist, 12, 1143-50. https://doi.org/10.1634/theoncologist.12-9-1143
  10. Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
  11. Hesketh PJ (2008). Chemotherapy induced nausea and vomiting. N Engl J Med, 358, 2482-94. https://doi.org/10.1056/NEJMra0706547
  12. Hesketh PJ, Grunberg S, Gralla R, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the aprepitant protocol 052 study group. J Clin Oncol, 21, 4112-9. https://doi.org/10.1200/JCO.2003.01.095
  13. Hesketh PJ, Kris MG, Grunberg SM, et al (1997). Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol, 15, 103-9.
  14. Hesketh PJ, Rossi G, Rizzi G, et al (2014). Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized doseranging pivotal study. Ann Oncol, 25, 1340-6. https://doi.org/10.1093/annonc/mdu110
  15. Janelsins MC, Tejani MA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacothe, 14, 757-66. https://doi.org/10.1517/14656566.2013.776541
  16. Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6. https://doi.org/10.7314/APJCP.2013.14.12.7701
  17. Koeller JM, Aapro MS, Gralla RJ, et al (2002). Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer, 10, 519-22. https://doi.org/10.1007/s00520-001-0335-y
  18. Kris MG, Hesketh PJ, Somerfield MR, et al (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol, 24, 2932-47. https://doi.org/10.1200/JCO.2006.06.9591
  19. Musso M, Scalone R, Crescimanno A, et al (2010). Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant. 45, 123-7. https://doi.org/10.1038/bmt.2009.114
  20. NCCN clinical Practice guidelines in oncology-antiemesis version I. 2014 (2014). http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp#supportive.
  21. Rizzi A, Campi B, Camarda V, et al (2012). "In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist netupitant". Peptides, 37, 86-97. https://doi.org/10.1016/j.peptides.2012.06.010
  22. Roila F, Donati D, Tamberi S, Margutti G (2002). Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer, 10, 88-95. https://doi.org/10.1007/s005200100295
  23. Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy- induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43. https://doi.org/10.1093/annonc/mdp300
  24. Roila F, Hesketh PJ, Herrstedt J (2006). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 perugia international antiemetic consensus conference. Ann Oncol, 17, 20-8. https://doi.org/10.1093/annonc/mdj944
  25. Rojas C, Raje M, Tsukamoto T, Slusher BS (2014). Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol, 722, 26-37. https://doi.org/10.1016/j.ejphar.2013.08.049
  26. Rojas C, Thomas AG, Alt J, et al (2010). Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol, 626, 193-9. https://doi.org/10.1016/j.ejphar.2009.10.002
  27. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al (2006). Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol, 17, 1000-6. https://doi.org/10.1093/annonc/mdl019
  28. Wang SC, Borison HL (1950). The vomiting center; a critical experimental analysis. Arch Neurol Psychiatry, 63, 928-41. https://doi.org/10.1001/archneurpsyc.1950.02310240087005

Cited by

  1. Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting vol.76, pp.18, 2016, https://doi.org/10.1007/s40265-016-0664-2
  2. The Role of Hypnosis in Cancer Care vol.20, pp.12, 2018, https://doi.org/10.1007/s11912-018-0739-1
  3. Nurse-led interventions on quality of life for patients with cancer vol.97, pp.34, 2018, https://doi.org/10.1097/MD.0000000000012037